Results 1 to 10 of about 20,820 (198)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [PDF]

Drugs in R&D
Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell, Benjamin C. Kennard, Maria E. Bertoni, David B. Cluck, Jonathan P. Moorman, Stacy D. Brown, Kesheng Wang, Michelle M. Duffourc, Sam Harirforoosh   +8 more
doaj   +2 more sources

Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort [PDF]

JHEP Reports
Background & Aims: The optimal antiviral agent for patients with chronic hepatitis B (CHB) at risk for osteoporosis remains debated. The aim of this study was to compare the incidence of osteoporosis and osteoporotic fractures between patients ...
Yoon E. Shin, Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim   +5 more
doaj   +2 more sources

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate [PDF]

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +2 more sources

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic Hepatitis B [PDF]

, 2013
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response.
Aldo Trylesinski, AS Levey, AS Lok, BJ McMahon, CJ Chen, CL Lai, DJ Tenney, DJ Tenney, DW Cockcroft, EB Keeffe, Eduardo Fassio, Fernando Bessone, H Izzedine, H Mommeja-Marin, H Yang, Henry L. Y. Chan, HL Chan, Hugo Cheinquer, Javier R. Lama, JD Jia, Jorge Daruich, KL Andersson, Liver European Association For The Study Of The, MF Yuen, MF Yuen, Mário G. Pessôa, N Leung, P Marcellin, Piyawat Komolmit, Rashidkhan Pathan, RD Cooper, RG Gish, S Mauss, S Zeuzem, Stefan Zeuzem, Suzane K. Ono, Tawesak Tanwandee, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, YF Liaw, YF Liaw, Yuhong Dong   +41 more
core   +25 more sources

Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review

Frontiers in Endocrinology, 2023
Tenofovir disoproxil fumarate is the first-line antiviral therapy for chronic viral hepatitis B, but long-term use is associated with renal failure and hypophosphatemic osteomalacia.
Jing Zeng, Peng Ye, Dong Wei, Lan Li, Wanxia Ma   +4 more
doaj   +1 more source

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate

Clinical Case Reports, 2022
Tenofovir disoproxil fumarate is a recommended first‐line therapy for patients with chronic hepatitis B, although the frequent Tenofovir disoproxil fumarate related adverse drug reactions are nephrotoxicity and bone toxicity.
Chunmei Li, Hui Li, Ming Gong, Jia Wei
doaj   +1 more source

A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation

Future Journal of Pharmaceutical Sciences, 2021
Background To establish a simple, sensitive, accurate, precise, efficient, economical RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulations ...
Swetha Addanki, B. Ramya Kuber
doaj   +1 more source

Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background A meta-analysis was made to assess the impact of entecavir comparison with tenofovir disoproxil fumarate as nucleos(t)ide analogue on hepatic cellular carcinoma (HCC). The study had subjects with chronic hepatitis B virus (HBV).
Sara M. Tony, Mohamed E. A. Shaaban, Ahmed I. M. Mohamed, Mohamed E. A. Abdelrahim   +3 more
doaj   +1 more source

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

EClinicalMedicine, 2021
Background: Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS ...
Jean-Jacques Parienti, Thierry Prazuck, Laure Peyro-Saint-Paul, Anna Fournier, Cécile Valentin, Sylvie Brucato, Renaud Verdon, Aymeric Sève, Mathilda Colin, Fabien Lesne, Jérome Guinard, Meriadeg Ar Gouilh, Julia Dina, Astrid Vabret, Laurent Hocqueloux   +14 more
doaj   +1 more source

Emtricitabine/Tenofovir Disoproxil Fumarate

Drugs in R & D, 2004
Gilead Sciences is developing a fixed-dose co-formulation of two of its reverse transcriptase inhibitors, emtricitabine [Emtriva] and tenofovir disoproxil fumarate [Viread], for once-daily dosing in combination with other antiretrovirals for the treatment of HIV infection.
Toni M, Dando, Antona J, Wagstaff
openaire   +4 more sources